Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer

Rhea-AI Summary

On April 20, 2023, Immunovia (Nasdaq: IMMNOV) announced its participation in a webinar titled "Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer," hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET. The webinar will feature presentations by Lara Sucheston-Campbell, VP of Clinical and Medical Affairs at Immunovia, and Dr. Rosario Ligresti from Hackensack University Medical Center. It aims to discuss the clinical application of novel biomarkers and liquid biopsies for early pancreatic cancer detection, covering sensitivity, specificity, and future detection strategies. Immunovia's IMMray™ PanCan-d test is the only blood test specifically for early pancreatic cancer detection, with a large addressable market in the USA.

LUND, Sweden, April 20, 2023 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world's first test dedicated to the early detection of pancreatic cancer, today announced it will participate in a webinar titled "Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer" hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.

Lara Sucheston-Campbell, Vice President of Clinical and Medical Affairs at Immunovia, and Dr. Rosario Ligresti, Director of the Pancreas Center at Hackensack University Medical Center are scheduled to present as expert speakers. The 75-minute webinar will provide the latest data, guidelines, and evidence related to the clinical application of novel biomarkers and liquid biopsies in the screening of pancreatic cancer.

The webinar will address how biomarker and liquid biopsy tests are applied in clinical practice to detect cancer at early stages. Additionally, the webinar will review the sensitivity, specificity, and accuracy of tests to detect clinically actionable biomarkers, the future of early detection in pancreatic cancer, and the impact on patients.

For more information and to register for the webinar please click here.

For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com

Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com

About Immunovia

Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. 

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated, addressable market size of 1.8 million individuals per year who could benefit from our test. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

The following files are available for download:

https://mb.cision.com/Main/13121/3754458/1996931.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.com/news-releases/immunovia-to-participate-in-national-pancreas-foundation-webinar-on-biomarkers-and-liquid-biopsy-for-early-detection-of-pancreatic-cancer-301802722.html

SOURCE Immunovia AB

FAQ

What is the focus of the upcoming Immunovia webinar on April 26, 2023?

The webinar will focus on biomarkers and liquid biopsy for early detection of pancreatic cancer.

Who are the speakers at the Immunovia webinar?

Lara Sucheston-Campbell from Immunovia and Dr. Rosario Ligresti from Hackensack University Medical Center are scheduled to speak.

What product does Immunovia promote for early pancreatic cancer detection?

Immunovia promotes the IMMray™ PanCan-d blood test, specifically for early pancreatic cancer detection.

When did Immunovia start commercialization of the IMMray™ PanCan-d test?

Commercialization of the IMMray™ PanCan-d test started in August 2021 in the USA.

How large is the addressable market for pancreatic cancer detection in the USA?

The addressable market for pancreatic cancer detection in the USA is estimated at 1.8 million individuals per year.